Clinical Trial Update: Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 results from a study evaluating MT-7117 for efficacy, safety, and tolerability in diffuse cutaneous systemic sclerosis have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis

Drugs mentioned

• MT-7117

Snippet

Sponsor: Tanabe Pharma America, Inc. | Conditions: Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2025-11-03